8:00 am
Registration & Morning Coffee
8:50 am Chair’s Opening Remarks
Designing Logical Combination Therapies
9:00 am Developments in Treating Prostate Cancer with RLT
Synopsis
- Integrating PSMA Radiotherapeutics into clinical practice
- Thoughts on how RLT could develop into a second/first-line therapy in coming
years
9:30 am Building Theranostic & Diagnostic Pairings
Synopsis
- Pros and cons of pairings
- The right emitter for the right indication
- The greater vision
10:00 am Logical Combination Therapies for Targeted Alpha Therapies
Synopsis
- Targeted alpha therapies induce (clustered) DNA double-strand breaks leading to cell death
- Combination with inhibitors of DNA damage response may increase efficacyPotential for immune system activation
10:30 am Pb-203/Pb-212: an Emerging Theranostic Isotopologue
Synopsis
- Theranostic pairs: what implications are there for matched and non-matched elements? Chemical, biological, developmental, logistical, commercial and regulatory aspects
- Pb-203/Pb-212 history, current state of development, and future potential.
- Next steps for radiopharmaceuticals: the curative potential of combination therapies. Targeted alpha particle therapy is showing great promise in combination with immunotherapy.
11:00 am
Morning Networking & Refreshment Break
11:30 am Locating Sites that Meet the Requirements of Radioligand Developers
Synopsis
- What can be done to create more spaces for RLT developers to conduct trials?
- It currently takes 600 hours to train in administering RLT therapies: How can this be best addressed to spread RLT further
- Meeting the requirements for both adult patients and paediatrics
Leveraging Clinical Trial Logistics & Resources
12:00 pm Scaling Up Efficiently to Meet Commercial Goals
Synopsis
- Discuss planning, and roll out of program to scale up RLT manufacturing facilities
- Consider potential bottlenecks and potential challenges of a collaborative vs. solo approach
12:30 pm Clinical Trials with Radiopharmaceuticals: Who is in charge?
Synopsis
- Oncology or Nuclear Medicine? Who decides?
- Clinical trial design for radiopharmaceuticals: Oncology or NM perspective?
- Clinical trial design for radiopharmaceuticals: Words matter!
Harnessing Dosimetry Studies to Improve Gain Clarity on Absorption
1:00 pm
Lunch Break
2:00 pm The Radiochemistry, Preclinical Efficacy & Immunogenicity Of 212Pb- Based Radiopharmaceuticals
Synopsis
- Develop radiochemistry for rapid reaction with Pb-212 and stable chelation of progeny Bi-212 daughters
- Pb-203 surrogate predicts in vivo biodistribution of Pb-212 and progeny Bi-212
- The immunogenicity of alpha-radiotherapy and synergy with immunotherapy in
melanoma
2:30 pm Panel Discussion: Striking a Balance: Achieving Anticancer Activity without Toxicity
Synopsis
- Consider how we can investigate toxicity through dosimetry and how this data can be used in regulator submissions
- Discuss how dosimetry will play a role in taking on new cancer types
- How can we overcome the lack of clarity around the application and value of
dosimetry?
3:15 pm
Afternoon Refreshment & Networking Break
Securing Funding to Protect & Drive Future Research
3:45 pm Panel Discussion: Riding the Wave: Capitalizing on the Recent Influx of Investment in Radiopharmaceuticals
Synopsis
- Discuss how recent investment has changed the radiopharmaceutical ecosystem
- Highlight key trends and consider where future funding will be best placed to ‘raise the tide’ for the entire field
4:15 pm The Obstacles to Radiopharmaceutical Innovation & How to Overcome Them
Synopsis
- Quantifying theranostics potential
- In the context of the recent influx of investment in the North America, where should you go looking during your next funding series
- Incentive borderlines: How to collaborate with academic
- Isotopes in medicine: A dilemma or a game-changer